Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos Vargas, a Mayo Clinic radiation ...
Jan 25, 2024
0
1
According to the Centers for Disease Control and Prevention, cancer is a leading cause of death in the United States. Unfortunately for American men, prostate cancer remains one of the deadliest cancers.
Jan 24, 2024
0
0
Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial led by UC San Francisco researchers ...
Jan 23, 2024
0
3
Human pathologists are extensively trained to detect when tissue samples from one patient mistakenly end up on another patient's microscope slides (a problem known as tissue contamination). But such contamination can easily ...
Jan 23, 2024
0
0
Tumors depend heavily on certain genetic changes to thrive, and researchers have discovered many such "genetic dependencies" as targets for potential new cancer drugs. At the Broad Institute of MIT and Harvard and elsewhere, ...
Jan 23, 2024
0
0
A 10-year follow-up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision-making in terms of treatments and side effects for a diverse population.
Jan 23, 2024
0
15
Because low-risk prostate cancer is unlikely to spread or impact survival, experts and guidelines recommend active surveillance, which involves regular monitoring and thus avoids or delays treatment like surgery or radiation ...
Jan 22, 2024
0
0
Rutgers researchers can predict which patients will benefit from a popular prostate cancer drug—and they have devised a strategy that may make the treatment work longer.
Jan 22, 2024
0
17
Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells' resistance to docetaxel, a commonly-used chemotherapy drug to treat advanced cancer that has spread beyond the prostate.
Jan 22, 2024
0
15
A new study published in Oncogene highlights the effectiveness of MDX-124, the first therapeutic drug to target annexin-A1, a protein that is overexpressed in several cancer types and promotes tumor progression.
Jan 19, 2024
0
32
